Xtant Medical (XTNT) 10-Q 6 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	Bacterin International Holdings, Inc.
Entity Central Index Key	1453593
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BONE
Entity Common Stock, Shares Outstanding		7,044,426

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$2,899,557	$4,468,208
Trade accounts receivable, net of allowance for doubtful accounts of $1,322,569 and $1,392,989, respectively	5,495,667	4,427,081
Inventories, net	9,710,580	9,558,648
Prepaid and other current assets	885,359	654,140
Total current assets	18,991,163	19,108,077
Non-current inventories	1,787,061	1,934,258
Property and equipment, net	4,503,132	4,654,527
Intangible assets, net	621,126	655,490
Other assets	1,502,333	1,598,539
Total Assets	27,404,815	27,950,891
Current Liabilities:
Accounts payable	4,412,385	3,876,760
Accounts payable - related party	327,641	250,629
Accrued liabilities	2,645,346	1,921,301
Warrant derivative liability	1,782,579	1,320,371
Current portion of capital lease obligations	30,914	61,970
Current portion of royalty liability	1,109,750	1,000,750
Current portion of long-term debt	51,574	50,671
Total current liabilities	10,360,189	8,482,452
Long-term Liabilities:
Capital lease obligation, less current portion	6,529	11,808
Long-term royalty liability, less current portion	6,228,293	6,361,216
Long-term debt, less current portion	21,281,052	20,870,330
Total Liabilities	37,876,063	35,725,806
Commitments and Contingencies
Stockholders' (Deficit) Equity
Preferred stock, $0.000001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.000001 par value; 95,000,000 shares authorized; 7,044,426 shares issued and outstanding as of March 31, 2015 and 6,679,646 shares issued and outstanding as of December 31, 2014	7	7
Additional paid-in capital	64,572,987	63,091,620
Accumulated deficit	-75,044,242	-70,866,542
Total Stockholders’ Deficit	-10,471,248	-7,774,915
Total Liabilities & Stockholders’ Deficit	$27,404,815	$27,950,891

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
Trade accounts receivable, allowance for doubtful accounts (in dollars)	$1,322,569	$1,392,989
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	7,044,426	6,679,646
Common Stock, shares outstanding	7,044,426	6,679,646

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Tissue sales	$9,277,047	$8,751,345
Royalties and other	226,067	161,625
Total Revenue	9,503,114	8,912,970
Cost of sales	3,472,477	3,410,705
Gross Profit	6,030,637	5,502,265
Operating Expenses
General and administrative	2,425,167	2,288,803
Sales and marketing	4,713,672	4,055,204
Research and development	433,561	254,583
Depreciation and amortization	124,111	75,148
Non-cash consulting expense	66,796	20,527
Total Operating Expenses	7,763,307	6,694,265
Loss from Operations	-1,732,670	-1,192,000
Other Income (Expense)
Interest expense	-1,435,578	-1,275,612
Change in warrant derivative liability	-462,208	-1,485,729
Non-cash consideration associated with stock purchase agreement	558,185	0
Other income (expense)	11,837	-186,915
Total Other Income (Expense)	-2,444,134	-2,948,256
Net Loss from Operations	($4,176,804)	($4,140,256)
Net loss per share:
Basic	($0.62)	($0.77)
Dilutive	($0.62)	($0.77)
Shares used in the computation:
Basic	6,689,530	5,379,714
Dilutive	6,689,530	5,379,714

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net loss	($4,176,804)	($4,140,256)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	235,124	169,148
Non-cash interest	135,002	-13,285
Non-cash consideration associated with stock purchase agreement	558,185	0
Gain on sale of fixed assets	-16,415	0
Amortization of debt discount	424,387	359,087
Non-cash consulting expense/stock option expense	229,984	322,222
Provision for losses on accounts receivable and inventory	-209,891	168,120
Change in derivative warrant liability	462,208	1,485,729
Changes in operating assets and liabilities:
Accounts receivable	-993,821	-836,581
Inventories	147,747	238,565
Prepaid and other assets	-152,026	-340,689
Accounts payable	610,718	1,444,605
Accrued liabilities	667,326	-1,045,554
Net cash used in operating activities	-2,078,276	-2,188,889
Investing activities:
Purchases of property and equipment and intangible assets	-48,768	-54,933
Proceeds from sale of fixed assets	16,415	36,073
Net cash used in investing activities	-32,353	-18,860
Financing activities:
Proceeds from issuance of debt	0	4,000,000
Payments on long-term debt	-171,687	-29,193
Payments on capital leases	-36,335	-40,776
Net proceeds from issuance of stock	750,000	0
Net cash provided by financing activities	541,978	3,930,031
Net change in cash and cash equivalents	-1,568,651	1,722,282
Cash and cash equivalents at beginning of period	4,468,208	3,046,340
Cash and cash equivalents at end of period	$2,899,557	$4,768,622

Business_Description_and_Summa

Business Description and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Summary of Significant Accounting Policies
	(1)     Business Description and Summary of Significant Accounting Policies
	Business Description
	The accompanying consolidated financial statements include the accounts of Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiary, Bacterin International, Inc., a Nevada corporation, (collectively, the “Company” or “Bacterin”). All intercompany balances and transactions have been eliminated in consolidation. Bacterin develops, manufactures and markets biologic products to domestic and international markets.  Bacterin’s proprietary methods are used to process human derived allografts into scaffolds that promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and regeneration in knee and other joint surgeries.
	Bacterin also develops and licenses coatings for various medical device applications.  As of December 31, 2014, Bacterin made a strategic decision to discontinue the medical device coatings business which resulted in an impairment of related assets. See Note 4, “Impairment of Assets”.
	An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. Up until December 31, 2014, the Company operated two distinct lines of business consisting of the biologics and the device divisions. With the strategic exit from the device business as of December 31, 2014, the Company will be operating as a single business segment in 2015.
	The Company's revenue is derived principally from the sale of its biologic products. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution methods, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change.  Further, a decline in available tissue donors could have an adverse impact on our business.
	The accompanying interim condensed consolidated financial statements of Bacterin for the quarters ended March 31, 2015 and 2014 are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual financial statements, but in the opinion of management, include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results which may be achieved in the future for the full year ending December 31, 2015.
	These financial statements should be read in conjunction with the financial statements and notes thereto which are included in Bacterin’s Annual Report on Form 10-K for the year ended December 31, 2014. The accounting policies set forth in those annual financial statements are the same as the accounting policies utilized in the preparation of these financial statements, except as modified for appropriate interim financial statement presentation.
	Reverse Stock Split
	The Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. The reverse stock split was approved by the Company's shareholders at the 2014 Annual Meeting of Shareholders on June 11, 2014.  All references to common stock, stock options, restricted stock units, warrants, and per share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented.
	Public Offering
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and were used for working capital and general corporate purposes, including the continued expansion of the company's sales force, product development, and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014. The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a valuation model to determine the fair market value and accounts for these warrants as a derivative liability (see "Derivative Instruments" below).  Also, see Note 10, "Warrants" below.
	Aspire Capital Transaction
	We entered into a Common Stock Purchase Agreement on March 16, 2015, as amended and restated on April 17, 2015 (the “Purchase Agreement”), with Aspire Capital Fund, LLC (“Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of our shares of common stock over the approximately 24-month term of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, we issued 207,182 shares of our common stock to Aspire Capital for $750,000 in aggregate proceeds. We also issued 154,189 shares of our common stock which were valued at $3.62 per share and included as $558,185 on the Statement of Operations to Aspire Capital as a commitment fee. See Note 2, “Equity” below.
	Concentrations and Credit Risk
	The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. Approximately  97% and   98% of sales were in the United States respectively for the first quarters ended 2015 and 2014.  No single customer accounted for more than 10% of revenue or accounts receivable for the comparable periods. The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at March 31, 2015.
	Revenue by geographical region is as follows:
		Quarter Ended
		March 31,
		2015		2014
	United States	$	9,258,210	$	8,742,073
	Rest of World		244,904		170,897
		$	9,503,114	$	8,912,970
	Use of Estimates
	The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment and intangible assets; valuation allowances for trade receivables and deferred income tax assets; valuation of the warrant derivative liability; inventory reserve; royalty liability; and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.
	Long-Lived Assets
	Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. See Note 4, “Impairment of Assets”.
	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.
	The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes.  If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.
	The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer.  The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when above criteria have been met.
	The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the quarters ended March 31, 2015 and 2014.
	Advertising Costs
	The Company expenses advertising costs as incurred. The Company had advertising expense of $2,658 and $26,711 for the quarters ended March 31, 2015 and 2014, respectively.
	Research and Development
	Research and development costs, which are principally related to internal costs for the development of new allograft technologies and processes are expensed as incurred.
	Net Loss Per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method.  Diluted net loss per share was the same as basic net loss per share for the quarters ended March 31, 2015 and 2014, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods.  Dilutive earnings per share are not reported as their effects of including 2,186,361 and 1,841,849 outstanding stock options and warrants for the quarters ended March 31, 2015 and 2014, respectively, are anti-dilutive.
	Fair Value of Financial Instruments
	The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.
	The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
	Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the quarters ended March 31, 2015 and 2014, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.
	The following table sets forth by level, within the fair value hierarchy, our liabilities as of March 31, 2015 and December 31, 2014 that are measured at fair value on a recurring basis:
	Warrant derivative liability
		As of		As of
		March 31,		December 31,
		2015		2014
	Level 1		-		-
	Level 2		-		-
	Level 3	$	1,782,579	$	1,320,371
	The valuation technique used to measure fair value of the warrant liability is based on a valuation model and significant assumptions and inputs determined by us (See Note 10, “Warrants” below).
	Level 3 Changes
	The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the quarter ended March 31, 2015:
	Warrant derivative liability
	Balance at January 1, 2015	$	1,320,371
	Loss recognized in earnings		462,208
	Balance at March 31, 2015	$	1,782,579
	During the quarter ended March 31, 2015, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.
	Recent Accounting Pronouncements
	In November 2014, FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 201) and Property, Plant and Equipment (Topic 360) - Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update are effective for the annual period ending after December 15, 2014, and interim periods within those years. Early adoption is permitted only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Equity	(2)   Equity
	During the first quarter of 2014, the Company issued 150,000 shares of common stock to an affiliate of ROS pursuant to a Sixth Amendment to our Credit Agreement with ROS whereby we borrowed an additional $4 million under our Credit Agreement.  This issuance has been accounted for as a debt discount and will be amortized over the life of the loan.  See Note 8, “Long-term Debt” below.
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and were used for working capital and general corporate purposes including the continued expansion of the company's sales force and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014. The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a valuation model to determine the fair market value and accounts for these warrants as a derivative liability (See Note 1, “Fair Value of Financial Instruments" above). Also, see Note 10, "Warrants" below.
	On March 16, 2015, we entered into a Purchase Agreement,  as amended and restated April 17, 2015, with Aspire Capital which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over the 24-month term. The stock purchase transactions are at the Company’s option. Pursuant to the terms and conditions in the Purchase Agreement, we also agreed to sell, and Aspire Capital agreed to buy, 207,182 shares of our common stock for $750,000 in aggregate proceeds. We also issued  154,189 shares of our common stock to Aspire Capital as a commitment fee.
	Under the Purchase Agreement, we have the right to sell up to an additional $9,250,000 of our common stock in the aggregate to Aspire Capital over a 24-month period. More specifically, we have the right, at our sole discretion, to present Aspire Capital with purchase notices, directing Aspire Capital (as principal) to purchase up to 50,000 shares of our common stock, per trading day, provided that the aggregate price of each such purchase shall not exceed $500,000 per trading day at a per share price equal to the lesser of:
		•	the lowest sale price of our common stock on the purchase date; or
		•	the arithmetic average of the three lowest closing sale prices for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date.
	In addition, we also have the right to present Aspire Capital with volume-weighted average price purchase notices directing Aspire Capital to purchase an amount of our common stock equal to up to 30% of the aggregate shares of our common stock traded on the OTCQX marketplace on the next trading day, subject to the terms, conditions and limitations in the Purchase Agreement.
	The Purchase Agreement may be terminated by us at any time, at our discretion, without any penalty or cost to us. The Purchase Agreement also provides for customary events of default, upon the occurrence of which Aspire Capital may terminate the Purchase Agreement. Aspire Capital has agreed that neither it nor any of its agents, representatives or affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the Purchase Agreement. Any proceeds we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	(3)   Inventories
	Inventories consist of the following:
		March 31,		December 31,
		2015		2014
	Current inventories
	Raw materials	$	4,198,257	$	3,836,635
	Work in process		2,444,393		2,484,635
	Finished goods		4,911,679		5,163,458
			11,554,329		11,484,728
	Reserve for obsolescence		-1,843,749		-1,926,080
	Current inventories, total		9,710,580		9,558,648
	Non-current inventories
	Finished goods		2,642,900		2,860,248
	Reserve for obsolescence		-855,839		-925,990
	Non-current inventories, total		1,787,061		1,934,258
	Total inventories	$	11,497,641	$	11,492,906

Impairment_of_Assets

Impairment of Assets	3 Months Ended
	Mar. 31, 2015
Impairment or Disposal of Tangible Assets Disclosure [Abstract]
Impairment of Assets	(4)   Impairment of Assets
	During the fourth quarter of 2014, management decided to dispose of a group of components because of a shift in strategy for the Company. The component groups are the inventory and fixed assets associated with the Device Coatings and Cranial Maxillofacial Fixation (CMF) lines of business.
	Sales for these product lines represented less than 1% of total revenue in both the 1st quarter of 2015 and 2014. Gross profit associated with these product lines were less than 1% of total gross profit for both periods.
	Management has committed to a plan to sell the component assets and the assets are available for immediate sale in their present condition. Management has identified a potential buyer for the device coatings product line. And as noted below the CMF assets were sold during the first quarter of 2015.
	Total assets associated with the two lines at December 31, 2014 included $80,042 of related fixed assets, net of depreciation, and related inventory of $832,507 for a total value of $912,549. These assets were transferred to Assets held for Sale and are classified on the balance sheet at December 31, 2014 as part of “Prepaid and other current assets”. After the impairment provision, the net balance of the Assets held for Sale is $0 at December 31, 2014.
	Because the device coatings agreement is in the early stage of negotiations and the sale of the CMF inventory during the first quarter of 2015 did not result in any tangible compensation, management decided to reserve for the entire amount and recorded a loss from impairment of assets  of $912,549 on the 2014 Consolidated Statement of Operations.

Property_and_Equipment_Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	(5)   Property and Equipment, Net
	Property and equipment, net are as follows:
		March 31,		December 31,
		2015		2014
	Buildings	$	1,657,579	$	1,657,579
	Equipment		4,711,916		4,724,608
	Computer equipment		225,009		225,009
	Computer software		359,046		345,039
	Furniture and fixtures		153,834		153,834
	Leasehold improvements		2,381,413		2,380,617
	Vehicles		10,000		41,099
	Total cost		9,498,797		9,527,785
	Less: accumulated depreciation		-4,995,665		-4,873,258
		$	4,503,132	$	4,654,527
	The Company leases certain equipment under capital leases. For financial reporting purposes, minimum lease payments relating to the assets have been capitalized. As of March 31, 2015, the Company has recorded $443,060 gross assets in Equipment, and $209,542 of accumulated depreciation relating to assets under capital leases.
	Maintenance and repairs expense for the first quarters of 2015 and 2014 was $99,523 and $70,444, respectively.  Depreciation expense related to property and equipment, including property under capital lease for the first quarters of 2015 and 2014 was $165,403 and $150,232, respectively.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(6)   Intangible Assets
	Bacterin has applied for various patents with regards to processes for its products.
	The following table sets forth information regarding intangible assets:
		March 31,		December 31,
		2015		2014
	Intellectual Property
	Gross carrying value	$	1,021,350	$	1,036,580
	Accumulated amortization		-400,224		-381,090
	Net carrying value	$	621,126	$	655,490
	Aggregate amortization expense:	$	52,709	$	77,022
	The following is a summary of estimated future amortization expense for intangible assets as of March 31, 2015:
	Remainder of 2015	$	65,875
	2016		56,972
	2017		56,972
	2018		56,972
	2019		54,405
	Thereafter		329,930
	Total	$	621,126

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	(7)   Accrued Liabilities
	Accrued liabilities consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued stock compensation	$	56,824	$	-
	Wages/commissions payable		1,795,005		1,434,743
	Other accrued expenses		793,517		486,558
		$	2,645,346	$	1,921,301

Longterm_Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Long-term Debt	(8)   Long-term Debt
	On March 6, 2014, we entered into a Sixth Amendment to our Credit Agreement with ROS whereby we borrowed an additional $4.0 million under our Credit Agreement with ROS and agreed to issue 150,000 shares to an affiliate of ROS.  We used the proceeds for working capital and general corporate purposes.
	Long-term debt consists of the following:
		March 31,		December 31,
		2015		2014
	Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	24,000,000	$	24,000,000
	Adjustment fee payable to ROS Acquisition Offshore, due in August 2019		700,000		700,000
	6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,313,051		1,325,814
			26,013,051		26,025,814
	Less: current portion		-51,574		-50,671
	Debt discount		-4,680,425		-5,104,813
	Long-term debt	$	21,281,052	$	20,870,330
	The following is a summary of maturities due on the debt as of March 31, 2015:
	Remainder of 2015	$	37,846
	2016		2,112,064
	2017		8,290,378
	2018		8,293,897
	2019		6,239,295
	Thereafter		1,039,571
	Total	$	26,013,051
	The following is a summary of estimated future royalty payments as of March 31, 2015:
	2015	$	787,500
	2016		1,229,250
	2017		1,360,250
	2018		1,462,750
	2019		1,575,250
	Thereafter		5,626,325
	Total	$	12,041,325

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(9)          Stock-Based Compensation
	Our Amended and Restated Equity Incentive Plan ("The Plan") provides for stock awards, including options and performance stock awards, to be granted to employees, consultants, independent contractors, officers and directors. The purpose of the Plan is to enable us to attract, retain and motivate key employees, directors and, on occasion, independent consultants, by providing them with stock options and restricted stock grants. Stock options granted under the Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The Plan is administered by the compensation committee of our Board of Directors. The administrator of the Plan has the power to determine the terms of any stock options granted under the Plan, including the exercise price, the number of shares subject to the stock option and conditions of exercise. Stock options granted under the Plan are generally not transferable, vest in installments over the requisite service period and are exercisable during the stated contractual term of the option only by such optionee. The exercise price of all incentive stock options granted under the Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. 900,000 shares are authorized under the Plan and at March 31, 2015, we had approximately 103,000 shares available for issuance. Shares issued under the Plan may be authorized, but unissued or reacquired shares.
	Stock compensation expense recognized in the statement of operations for the quarters ended March 31, 2015 and 2014 is based on awards ultimately expected to vest and reflects an estimate of awards that will be forfeited. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The estimated fair value of stock options granted is done using the Black-Sholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:
		Quarter Ended		Quarter Ended
		March 31, 2015		March 31, 2014
	Risk-free interest rate	2.38	%	0.91	%
	Expected volatility	64	%	64	%
	Expected term	6.1 Years		6.6 Years
	Expected forfeiture rate	20	%	20	%
	Dividend yield	0	%	0	%
	In July 2014, the Company granted our President an option to purchase 55,000 shares of our common stock outside of the Plan, and in August 2013, the Company granted our Chief Executive Officer an option to purchase 200,000 shares of our common stock outside of the Plan (collectively the “Non-Plan Grants”).
	Stock option activity under the Plan, plus the Non-Plan Grants, was as follows:
		2015						2014
						Weighted						Weighted
				Weighted		Average				Weighted		Average
						Fair						Fair
				Average		Value at				Average		Value at
				Exercise		Grant				Exercise		Grant
		Shares		Price		Date		Shares		Price		Date
	Outstanding at January 1		695,336	$	11.09	$	5.35		758,328	$	14.9	$	8.6
	Granted		-		-		-		-		-		-
	Exercised		-		-		-		-		-		-
	Cancelled or expired		-		-		-		-300		14.7		9
	Outstanding at March 31		695,336	$	11.09	$	5.35		758,028	$	14.9	$	7.4
	Exercisable at March 31		322,381	$	14.97	$	6.89		263,971	$	21	$	7.4
	The aggregate intrinsic value of options outstanding as of March 31, 2015 is approximately $35,653. The aggregate intrinsic value of exercisable options as of March 31, 2015 is approximately $35,650. As of March 31, 2015, there were 372,955 unvested options with a weighted average fair value at the grant date of $4.26 per option. As of March 31, 2015, there is approximately $938,085 of compensation expense related to unvested awards not yet recognized.
	From time to time we may grant stock options and stock grants to consultants. We account for consultant stock options in accordance with ASC 505-50. Consulting expense for the grant of stock options to consultants is determined based on the estimated fair value of the stock options at the measurement date as defined in ASC 505-50 and is recognized over the vesting period.
	The Company recognized non-cash consulting expense for the quarters ended March 31, 2015 and 2014 as $66,796 and $20,527.
	Total share based compensation recognized for employees, directors and consultants was $229,984 and $322,222 for the quarters ended March 31, 2015 and 2014, respectively.
	On November 10, 2014, the company issued 39,312 shares of restricted stock to the independent Directors of the Company. These restricted shares vest on July 1, 2015 and were issued when the stock price was $4.07 per share. The total expense of $160,000 is going to be recognized ratably over the period in General and Administrative expense.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Warrants	(10)           Warrants
	The following table summarizes our warrant activities for the period ended March 31, 2015:
					Weighted
					Average
					Exercise
		Shares			Price
	Outstanding as of January 1, 2014		1,087,820		$	16.2
	Issued		571,500			7.12
	Expired		-4,000			20
	Outstanding at January 1, 2015		1,655,320		$	13.06
	Issued		-			-
	Expired		-164,295			17.9
	Outstanding at March 31, 2015		1,491,025		$	12.52
	We utilize a valuation model to determine the fair market value of the warrants accounted for as liabilities. The valuation model accommodates the probability of exercise price adjustment features as outlined in the warrant agreements. We recorded an unrealized loss of $462,208 resulting from the change in the fair value of the warrant derivative liability for first quarter of 2015. Under the terms of some of our warrant agreements, at any time while the warrant is outstanding, the exercise price per share can be reduced to the price per share of future subsequent equity sales of our common stock or a common stock equivalent that is lower than the exercise price per share as stated in the warrant agreement.
	The estimated fair value was derived using the valuation model with the following weighted-average assumptions:
		Quarter ended
		March 31,
		2015				2014
	Value of underlying common stock (per share)	$	3.03			$	8.4
	Risk free interest rate		1.3	%			1.92	%
	Expected term		4.75 years				5.46 years
	Dividend yield		0				0
	Volatility		64	%			64	%
	The following table summarizes our activities related to warrants accounted for as a derivative liability for the quarters ended March 31, 2015 and 2014:
		2015			2014
	Balance at January 1,		1,171,692			600,192
	Derivative warrants issued		-			-
	Derivative warrants exercised		-			-
	Balance at March 31,		1,171,692			600,192

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11)   Commitments and Contingencies
	Operating Leases
	We lease two office facilities under non-cancelable operating lease agreements with expiration dates in 2019 and 2023. We have the option to extend both the leases for another ten year term and for one facility, we have the right of first refusal on any sale. We lease additional office space under a month-to-month arrangement. Future minimum payments for the next five years and thereafter as of March 31, 2015, under these leases, are as follows:
	Remainder of 2015	$	243,300
	2016		283,448
	2017		280,527
	2018		286,754
	2019		166,940
	Thereafter		559,000
	Total	$	1,819,969
	Rent expense was $83,613 and $78,466 for the quarters ended March 31, 2015 and 2014, respectively. Rent expense is determined using the straight-line method of the minimum expected rent paid over the term of the agreement. We have no contingent rent agreements.
	Indemnifications
	Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party's intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying financial statements.
	We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by us, arising out of that person's services as our director or officer or that person's services provided to any other company or enterprise at our request.
	Pending and Threatened Litigation
	On March 17, 2014, a complaint was served on the Company in the following state court action in the District Court for the County of Arapahoe, State of Colorado: Robert Taggart v. Guy Cook, Bacterin International, Inc., a Nevada Corporation and Bacterin International Holdings, Inc., a Delaware corporation, Civil Action No. 14CV30401. The complaint involves claims under an employment agreement between plaintiff and the Company seeking commissions on Company sales, a commission on funds obtained by the Company as a result of a reverse merger and vesting of certain stock options. Plaintiff seeks damages in excess of $5 million. The Company believes this case lacks legal merit and has filed counterclaims for plaintiff’s breach of his employment agreement and breach of his duty of loyalty to the Company, asserting the right to recover all compensation paid to Plaintiff during his employment as well as other damages.
	On July 9, 2014, a complaint was served on the Company in the following action in the United States District Court, District of New Jersey:  Middlebury Securities, LLC v. Bacterin International, Inc., Case Number 2:14-CV-03905-WJM-MF.  The complaint alleges that Bacterin owes Middlebury an $80,000 fee, along with $80,000 in warrants, in connection with the March 6, 2014 extension of credit by ROS.   Bacterin believes this case lacks merit because there is no agreement between the parties regarding the transaction in question.
	On July 14, 2014, a complaint was served on the Company in the following action in the United States Bankruptcy Court, Southern District of New York, In re:  Rodman & Renshaw, LLC, Debtor, Case No. 13-10087 (REG):  YANN GERON, Chapter 7 Trustee of the Estate of Rodman & Renshaw, LLC, Plaintiff, against Bacterin International Holdings, Inc.  The complaint alleges that Bacterin owes a $150,000 investment banking fee in connection with Bacterin’s April 2012 accounts receivable credit facility with MidCap Financial LLC.  Bacterin believes this case lack merit because the accounts receivable credit facility was not a debt or equity security covered by the engagement letter.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	(12)        Income Taxes
	In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance.
	The 2011 through 2014 tax years remain open to examination by the Internal Revenue Service and the 2009 to 2014 tax years remain open to the Montana Department of Revenue.  These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.
	The Company did not recognize any interest or penalties related to income taxes for the quarters ended March 31, 2015 and 2014.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	(13)   Supplemental Disclosure of Cash Flow Information
	Supplemental cash flow information is as follows:
		Quarter Ended
		March 31,
		2015		2014
	Supplemental disclosure of cash flow information
	Cash paid during the period for:
	Interest	$	801,844	$	930,547
	Non-cash activities:
	Issuance of shares related to debt issuance	$	-	$	1,094,999

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	(14)   Related Party Transactions
	Darrel Holmes, our Chief Operating Officer, and Mitchell Godfrey, a former director, serve on the board of ADS, and Mr. Godfrey also serves as secretary and treasurer for ADS. Mssrs. Godfrey and Holmes receive $5,000 per year for their service to ADS. ADS recovers tissue from donors and we reimburse them for their recovery fees, which are comprised primarily of labor costs. The approximate aggregate amount of all transactions with ADS for the quarters ended March 31, 2015 and 2014 was $452,874 and $610,514 respectively. These relationships have benefited us, as these entities provide us with donors, thus insuring that we have a pipeline of current and future donors, which is necessary to our success.
	Unless delegated to the Compensation Committee by the Board of Directors, the Audit Committee or the disinterested members of the full Board of Directors reviews and approves all related party transactions.

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	(15)   Subsequent Event
	On April 8, 2015, we received a notice indicating that the NYSE MKT denied our appeal of their delisting determination. We were also notified that trading of our common stock would be suspended on the NYSE MKT. Beginning April 9, 2015, our stock began trading on the OTCQX marketplace.

Business_Description_and_Summa1

Business Description and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description	Business Description
	The accompanying consolidated financial statements include the accounts of Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiary, Bacterin International, Inc., a Nevada corporation, (collectively, the “Company” or “Bacterin”). All intercompany balances and transactions have been eliminated in consolidation. Bacterin develops, manufactures and markets biologic products to domestic and international markets.  Bacterin’s proprietary methods are used to process human derived allografts into scaffolds that promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and regeneration in knee and other joint surgeries.
	Bacterin also develops and licenses coatings for various medical device applications.  As of December 31, 2014, Bacterin made a strategic decision to discontinue the medical device coatings business which resulted in an impairment of related assets. See Note 4, “Impairment of Assets”.
	An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. Up until December 31, 2014, the Company operated two distinct lines of business consisting of the biologics and the device divisions. With the strategic exit from the device business as of December 31, 2014, the Company will be operating as a single business segment in 2015.
	The Company's revenue is derived principally from the sale of its biologic products. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution methods, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change.  Further, a decline in available tissue donors could have an adverse impact on our business.
	The accompanying interim condensed consolidated financial statements of Bacterin for the quarters ended March 31, 2015 and 2014 are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual financial statements, but in the opinion of management, include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results which may be achieved in the future for the full year ending December 31, 2015.
	These financial statements should be read in conjunction with the financial statements and notes thereto which are included in Bacterin’s Annual Report on Form 10-K for the year ended December 31, 2014. The accounting policies set forth in those annual financial statements are the same as the accounting policies utilized in the preparation of these financial statements, except as modified for appropriate interim financial statement presentation.
Reverse Stock Split	Reverse Stock Split
	The Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. The reverse stock split was approved by the Company's shareholders at the 2014 Annual Meeting of Shareholders on June 11, 2014.  All references to common stock, stock options, restricted stock units, warrants, and per share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented.
Public Offering	Public Offering
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and were used for working capital and general corporate purposes, including the continued expansion of the company's sales force, product development, and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014. The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a valuation model to determine the fair market value and accounts for these warrants as a derivative liability (see "Derivative Instruments" below).  Also, see Note 10, "Warrants" below.
Aspire Capital Transaction	Aspire Capital Transaction
	We entered into a Common Stock Purchase Agreement on March 16, 2015, as amended and restated on April 17, 2015 (the “Purchase Agreement”), with Aspire Capital Fund, LLC (“Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of our shares of common stock over the approximately 24-month term of the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, we issued 207,182 shares of our common stock to Aspire Capital for $750,000 in aggregate proceeds. We also issued 154,189 shares of our common stock which were valued at $3.62 per share and included as $558,185 on the Statement of Operations to Aspire Capital as a commitment fee. See Note 2, “Equity” below.
Concentrations and Credit Risk	Concentrations and Credit Risk
	The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. Approximately  97% and   98% of sales were in the United States respectively for the first quarters ended 2015 and 2014.  No single customer accounted for more than 10% of revenue or accounts receivable for the comparable periods. The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at March 31, 2015.
	Revenue by geographical region is as follows:
		Quarter Ended
		March 31,
		2015		2014
	United States	$	9,258,210	$	8,742,073
	Rest of World		244,904		170,897
		$	9,503,114	$	8,912,970
Use of Estimates	Use of Estimates
	The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment and intangible assets; valuation allowances for trade receivables and deferred income tax assets; valuation of the warrant derivative liability; inventory reserve; royalty liability; and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.
Long-Lived Assets	Long-Lived Assets
	Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. See Note 4, “Impairment of Assets”.
Revenue Recognition	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.
	The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes.  If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.
	The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer.  The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when above criteria have been met.
	The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the quarters ended March 31, 2015 and 2014.
Advertising Costs	Advertising Costs
	The Company expenses advertising costs as incurred. The Company had advertising expense of $2,658 and $26,711 for the quarters ended March 31, 2015 and 2014, respectively.
Research and Development	Research and Development
	Research and development costs, which are principally related to internal costs for the development of new allograft technologies and processes are expensed as incurred.
Net Loss Per Share	Net Loss Per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method.  Diluted net loss per share was the same as basic net loss per share for the quarters ended March 31, 2015 and 2014, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods.  Dilutive earnings per share are not reported as their effects of including 2,186,361 and 1,841,849 outstanding stock options and warrants for the quarters ended March 31, 2015 and 2014, respectively, are anti-dilutive.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.
	The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
	Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the quarters ended March 31, 2015 and 2014, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.
	The following table sets forth by level, within the fair value hierarchy, our liabilities as of March 31, 2015 and December 31, 2014 that are measured at fair value on a recurring basis:
	Warrant derivative liability
		As of		As of
		March 31,		December 31,
		2015		2014
	Level 1		-		-
	Level 2		-		-
	Level 3	$	1,782,579	$	1,320,371
	The valuation technique used to measure fair value of the warrant liability is based on a valuation model and significant assumptions and inputs determined by us (See Note 10, “Warrants” below).
	Level 3 Changes
	The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the quarter ended March 31, 2015:
	Warrant derivative liability
	Balance at January 1, 2015	$	1,320,371
	Loss recognized in earnings		462,208
	Balance at March 31, 2015	$	1,782,579
	During the quarter ended March 31, 2015, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In November 2014, FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 201) and Property, Plant and Equipment (Topic 360) - Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update are effective for the annual period ending after December 15, 2014, and interim periods within those years. Early adoption is permitted only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.

Business_Description_and_Summa2

Business Description and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenues by Geographic Region	Revenue by geographical region is as follows:
		Quarter Ended
		March 31,
		2015		2014
	United States	$	9,258,210	$	8,742,073
	Rest of World		244,904		170,897
		$	9,503,114	$	8,912,970
Schedule of Assets and Liabilities Measured on Recurring Basis	Warrant derivative liability
		As of		As of
		March 31,		December 31,
		2015		2014
	Level 1		-		-
	Level 2		-		-
	Level 3	$	1,782,579	$	1,320,371
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the quarter ended March 31, 2015:
	Warrant derivative liability
	Balance at January 1, 2015	$	1,320,371
	Loss recognized in earnings		462,208
	Balance at March 31, 2015	$	1,782,579

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following:
		March 31,		December 31,
		2015		2014
	Current inventories
	Raw materials	$	4,198,257	$	3,836,635
	Work in process		2,444,393		2,484,635
	Finished goods		4,911,679		5,163,458
			11,554,329		11,484,728
	Reserve for obsolescence		-1,843,749		-1,926,080
	Current inventories, total		9,710,580		9,558,648
	Non-current inventories
	Finished goods		2,642,900		2,860,248
	Reserve for obsolescence		-855,839		-925,990
	Non-current inventories, total		1,787,061		1,934,258
	Total inventories	$	11,497,641	$	11,492,906

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net are as follows:
		March 31,		December 31,
		2015		2014
	Buildings	$	1,657,579	$	1,657,579
	Equipment		4,711,916		4,724,608
	Computer equipment		225,009		225,009
	Computer software		359,046		345,039
	Furniture and fixtures		153,834		153,834
	Leasehold improvements		2,381,413		2,380,617
	Vehicles		10,000		41,099
	Total cost		9,498,797		9,527,785
	Less: accumulated depreciation		-4,995,665		-4,873,258
		$	4,503,132	$	4,654,527

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table sets forth information regarding intangible assets:
		March 31,		December 31,
		2015		2014
	Intellectual Property
	Gross carrying value	$	1,021,350	$	1,036,580
	Accumulated amortization		-400,224		-381,090
	Net carrying value	$	621,126	$	655,490
	Aggregate amortization expense:	$	52,709	$	77,022
Schedule of Estimated Amortization Expense for Intangible Assets	The following is a summary of estimated future amortization expense for intangible assets as of March 31, 2015:
	Remainder of 2015	$	65,875
	2016		56,972
	2017		56,972
	2018		56,972
	2019		54,405
	Thereafter		329,930
	Total	$	621,126

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued stock compensation	$	56,824	$	-
	Wages/commissions payable		1,795,005		1,434,743
	Other accrued expenses		793,517		486,558
		$	2,645,346	$	1,921,301

Longterm_Debt_Tables

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following:
		March 31,		December 31,
		2015		2014
	Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	24,000,000	$	24,000,000
	Adjustment fee payable to ROS Acquisition Offshore, due in August 2019		700,000		700,000
	6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,313,051		1,325,814
			26,013,051		26,025,814
	Less: current portion		-51,574		-50,671
	Debt discount		-4,680,425		-5,104,813
	Long-term debt	$	21,281,052	$	20,870,330
Schedule of Maturities of Long-term Debt	The following is a summary of maturities due on the debt as of March 31, 2015:
	Remainder of 2015	$	37,846
	2016		2,112,064
	2017		8,290,378
	2018		8,293,897
	2019		6,239,295
	Thereafter		1,039,571
	Total	$	26,013,051
Schedule of Royalty Payments	The following is a summary of estimated future royalty payments as of March 31, 2015:
	2015	$	787,500
	2016		1,229,250
	2017		1,360,250
	2018		1,462,750
	2019		1,575,250
	Thereafter		5,626,325
	Total	$	12,041,325

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Key assumptions used to estimate the fair value of stock awards are as follows:
		Quarter Ended		Quarter Ended
		March 31, 2015		March 31, 2014
	Risk-free interest rate	2.38	%	0.91	%
	Expected volatility	64	%	64	%
	Expected term	6.1 Years		6.6 Years
	Expected forfeiture rate	20	%	20	%
	Dividend yield	0	%	0	%
Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity under the Plan, plus the Non-Plan Grants, was as follows:
		2015						2014
						Weighted						Weighted
				Weighted		Average				Weighted		Average
						Fair						Fair
				Average		Value at				Average		Value at
				Exercise		Grant				Exercise		Grant
		Shares		Price		Date		Shares		Price		Date
	Outstanding at January 1		695,336	$	11.09	$	5.35		758,328	$	14.9	$	8.6
	Granted		-		-		-		-		-		-
	Exercised		-		-		-		-		-		-
	Cancelled or expired		-		-		-		-300		14.7		9
	Outstanding at March 31		695,336	$	11.09	$	5.35		758,028	$	14.9	$	7.4
	Exercisable at March 31		322,381	$	14.97	$	6.89		263,971	$	21	$	7.4

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrant Activity	The following table summarizes our warrant activities for the period ended March 31, 2015:
					Weighted
					Average
					Exercise
		Shares			Price
	Outstanding as of January 1, 2014		1,087,820		$	16.2
	Issued		571,500			7.12
	Expired		-4,000			20
	Outstanding at January 1, 2015		1,655,320		$	13.06
	Issued		-			-
	Expired		-164,295			17.9
	Outstanding at March 31, 2015		1,491,025		$	12.52
Schedule of Warrant Valuation Assumptions	The estimated fair value was derived using the valuation model with the following weighted-average assumptions:
		Quarter ended
		March 31,
		2015				2014
	Value of underlying common stock (per share)	$	3.03			$	8.4
	Risk free interest rate		1.3	%			1.92	%
	Expected term		4.75 years				5.46 years
	Dividend yield		0				0
	Volatility		64	%			64	%
Schedule of Warrants Activities Used In Derivative Liability	The following table summarizes our activities related to warrants accounted for as a derivative liability for the quarters ended March 31, 2015 and 2014:
		2015			2014
	Balance at January 1,		1,171,692			600,192
	Derivative warrants issued		-			-
	Derivative warrants exercised		-			-
	Balance at March 31,		1,171,692			600,192

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum payments for the next five years and thereafter as of March 31, 2015, under these leases, are as follows:
	Remainder of 2015	$	243,300
	2016		283,448
	2017		280,527
	2018		286,754
	2019		166,940
	Thereafter		559,000
	Total	$	1,819,969

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Supplemental cash flow information is as follows:
		Quarter Ended
		March 31,
		2015		2014
	Supplemental disclosure of cash flow information
	Cash paid during the period for:
	Interest	$	801,844	$	930,547
	Non-cash activities:
	Issuance of shares related to debt issuance	$	-	$	1,094,999

Business_Description_and_Summa3

Business Description and Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	$9,503,114	$8,912,970
US [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	9,258,210	8,742,073
Rest Of World [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	$244,904	$170,897

Business_Description_and_Summa4

Business Description and Summary of Significant Accounting Policies (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$1,782,579	$1,320,371
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$1,782,579	$1,320,371

Business_Description_and_Summa5

Business Description and Summary of Significant Accounting Policies (Details 2) (Warrant [Member], Derivative [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member] | Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at January 1, 2015	$1,320,371
Loss recognized in earnings	462,208
Balance at March 31, 2015	$1,782,579

Business_Description_and_Summa6

Business Description and Summary of Significant Accounting Policies (Details Textual) (USD $)	0 Months Ended	2 Months Ended	3 Months Ended		1 Months Ended
	Aug. 06, 2014	Jul. 28, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 16, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Advertising Expense			$2,658	$26,711
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			2,186,361	1,841,849
Royalty Revenue Description			The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the quarters ended March 31, 2015 and 2014.	The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the quarters ended March 31, 2015 and 2014.
Proceeds From Issuance Or Sale Of Equity Gross	6,500,000
Stock Issued During Period, Shares, New Issues				150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$12.52			$13.06	$16.20
Proceeds from Issuance or Sale of Equity, Total	5,900,000
Stockholders' Equity, Reverse Stock Split		1:10 reverse split of its common stock
Other Non Cash Expense Associated With Stock Purchase Agreement			558,185	0
Aspire Capital Fund LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Issued During Period, Shares, New Issues					207,182
Common Stock To Be Issued For Commitment Fee			154,189
Common Stock, Shares Subscribed but Unissued					10,000,000
Stock Issued During Period, Value, New Issues					750,000
Share Price			$3.62
Other Non Cash Expense Associated With Stock Purchase Agreement			558,185
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Issued During Period, Shares, New Issues	1,143,000
Shares Issued, Price Per Share	$5.70
Common Stock [Member] | Aspire Capital Fund LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Issued During Period, Shares, New Issues					207,182
Stock Issued During Period, Value, New Issues					$750,000
August 2014 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	571,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$7.12
Class Of Warrant Or Right Term	5 years
Sales Revenue, Net [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Concentration Risk, Percentage			1.00%	1.00%
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | US [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Concentration Risk, Percentage			97.00%	98.00%

Equity_Details_Textual

Equity (Details Textual) (USD $)	0 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended	3 Months Ended
	Aug. 06, 2014	Mar. 31, 2014	Mar. 06, 2014	Mar. 16, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)		150,000
Proceeds from Issuance or Sale of Equity, Total	$5,900,000
Proceeds From Issuance Or Sale Of Equity Gross	6,500,000
Proceeds from Lines of Credit		4,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					12.52	$13.06	$16.20
Ros Acquisition Offshore [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Lines of Credit			4,000,000
Common Stock [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)	1,143,000
Shares Issued, Price Per Share	$5.70
August 2014 Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	571,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$7.12
Aspire Capital Fund LLC [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)				207,182
Common Stock, Shares Subscribed but Unissued				10,000,000
Stock Issued During Period, Value, New Issues				750,000
Common Stock To Be Issued For Commitment Fee					154,189
Additional Common Stock To Be Issued				9,250,000
Maximum Common Stock To Be Issued Per Trading Day				50,000
Maximum Common Stock Value To Be Issued Per Trading Day				500,000
Maximum Percentage Of Common Stock Weighted Average Price				30.00%
Aspire Capital Fund LLC [Member] | Common Stock [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)				207,182
Stock Issued During Period, Value, New Issues				$750,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current inventories
Raw materials	$4,198,257	$3,836,635
Work in process	2,444,393	2,484,635
Finished goods	4,911,679	5,163,458
Inventory, Gross	11,554,329	11,484,728
Reserve for obsolescence	-1,843,749	-1,926,080
Current inventories, total	9,710,580	9,558,648
Non-current inventories
Finished goods	2,642,900	2,860,248
Reserve for obsolescence	-855,839	-925,990
Non-current inventories, total	1,787,061	1,934,258
Total inventories	$11,497,641	$11,492,906

Impairment_of_Assets_Details_T

Impairment of Assets (Details Textual) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	$80,042
Disposal Group, Including Discontinued Operation, Inventory	832,507
Disposal Group, Including Discontinued Operation, Assets	0
Asset Impairment Charges	912,549
Prepaid Expenses and Other Current Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets	$912,549
Gross Profit [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration Risk, Percentage		1.00%	1.00%
Sales Revenue, Net [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration Risk, Percentage		1.00%	1.00%

Property_and_Equipment_Net_Det

Property and Equipment, Net (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total cost	$9,498,797	$9,527,785
Less: accumulated depreciation	-4,995,665	-4,873,258
Property and equipment, net	4,503,132	4,654,527
Building [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,657,579	1,657,579
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	4,711,916	4,724,608
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	225,009	225,009
Computer software[Member]
Property, Plant and Equipment [Line Items]
Total cost	359,046	345,039
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	153,834	153,834
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	2,381,413	2,380,617
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total cost	$10,000	$41,099

Property_and_Equipment_Net_Det1

Property and Equipment, Net (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	$443,060
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	209,542
Cost of Property Repairs and Maintenance	99,523	70,444
Depreciation	$165,403	$150,232

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Intellectual Property
Gross carrying value	$1,021,350	$1,036,580
Accumulated amortization	-400,224	-381,090
Net carrying value	621,126	655,490
Aggregate amortization expense:	$52,709	$77,022

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2015
Estimated amortization expense:
Remainder of 2015	$65,875
2016	56,972
2017	56,972
2018	56,972
2019	54,405
Thereafter	329,930
Total	$621,126

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Line Items]
Accrued stock compensation	$56,824	$0
Wages/commissions payable	1,795,005	1,434,743
Other accrued expenses	793,517	486,558
Accrued Liabilities Current	$2,645,346	$1,921,301

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Loan Payable	$26,013,051	$26,025,814
Less: current portion	-51,574	-50,671
Debt discount	-4,680,425	-5,104,813
Long-term debt	21,281,052	20,870,330
Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Loan Payable	24,000,000	24,000,000
Adjustment fee payable to ROS Acquisition Offshore, due in August 2019	700,000	700,000
Valley Bank Of Belgrade [Member]
Debt Instrument [Line Items]
Loan Payable	$1,313,051	$1,325,814

Longterm_Debt_Details_1

Long-term Debt (Details 1) (USD $)	Mar. 31, 2015
Schedule of maturities due on debt [Line Items]
Remainder of 2015	$37,846
2016	2,112,064
2017	8,290,378
2018	8,293,897
2019	6,239,295
Thereafter	1,039,571
Total	$26,013,051

Longterm_Debt_Details_2

Long-term Debt (Details 2) (USD $)	Mar. 31, 2015
Estimated future royalty payments [Line Items]
2015	$787,500
2016	1,229,250
2017	1,360,250
2018	1,462,750
2019	1,575,250
Thereafter	5,626,325
Total	$12,041,325

Longterm_Debt_Details_Textual

Long-term Debt (Details Textual) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Mar. 06, 2014
Debt Instrument [Line Items]
Proceeds from Lines of Credit	$4,000,000
Valley Bank Of Belgrade [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		6.00%
Debt Instrument, Periodic Payment		10,746
Debt Instrument, Maturity Date, Description		24-Dec-30
Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Description		LIBOR plus 12.13% maturing August 2019
Debt Conversion, Converted Instrument, Shares Issued			150,000
Proceeds from Lines of Credit			$4,000,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Risk-free interest rate	2.38%	0.91%
Expected volatility	64.00%	64.00%
Expected term	6 years 1 month 6 days	6 years 7 months 6 days
Expected forfeiture rate	20.00%	20.00%
Dividend yield	0.00%	0.00%

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Stock Option, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Option
Schedule of activity under stock option plans [Line Items]
Outstanding at January 1, 2015 Shares	695,336	758,328
Granted, Shares	0	0
Exercised, Shares	0	0
Cancelled or expired, Shares	0	-300
Outstanding at March 31, 2015 Shares	695,336	758,028
Exercisable at March 31, 2015 Shares	322,381	263,971
Outstanding at January 1, 2015 Weighted Average Exercise Price	$11.09	$14.90
Granted, Weighted Average Exercise Price	$0	$0
Exercised, Weighted Average Exercise Price	$0	$0
Cancelled or expired, Weighted Average Exercise Price	$0	$14.70
Outstanding at March 31, 2015 Weighted Average Exercise Price	$11.09	$14.90
Exercisable at March 31, 2015 Weighted Average Exercise Price	$14.97	$21
Outstanding at January 1, 2015 Weighted Average Fair Value At Grant Date	$5.35	$8.60
Granted, Weighted Average Fair Value At Grant Date	$0	$0
Exercised, Weighted Average Fair Value At Grant Date	$0	$0
Cancelled or expired, Weighted Average Fair Value At Grant Date	$0	$9
Outstanding at March 31, 2015 Weighted Average Fair Value At Grant Date	$5.35	$7.40
Exercisable at March 31, 2015 Weighted Average Fair Value At Grant Date	$6.89	$7.40

StockBased_Compensation_Detail2

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		1 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2013	Jul. 31, 2014	Nov. 10, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares authorized under the Plan	900,000
Aggregate intrinsic value of options outstanding	103,000
Allocated Share-based Compensation Expense	$229,984	$322,222
Chief Executive Officer [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted			200,000
President [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted				55,000
Employee Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	35,653
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	35,650
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	938,085
Number of Unvested options	372,955
Weighted average grant date fair value of unvested options	$4.26
Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Allocated Share-based Compensation Expense	66,796	20,527
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period					39,312
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options					$160,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issue Price On Grand Date					$4.07
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					vest on July 1, 2015

Warrants_Details

Warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant activity [Line Items]
Outstanding	1,655,320	1,087,820
Issued, Shares	0	571,500
Expired, Shares	-164,295	-4,000
Outstanding	1,491,025
Outstanding Weighted Average Exercise Price	$13.06	$16.20
Issued, Weighted Average Exercise Price	$0	$7.12
Expired, Weighted Average Exercise Price	$17.90	$20
Outstanding Weighted Average Exercise Price	$12.52

Warrants_Details_1

Warrants (Details 1) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)	$3.03	$8.40
Risk free interest rate	1.30%	1.92%
Expected term	4 years 9 months	5 years 5 months 16 days
Dividend yield	0.00%	0.00%
Volatility	64.00%	64.00%

Warrants_Details_2

Warrants (Details 2)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Class of Warrant or Right [Line Items]
Outstanding	1,655,320	1,087,820
Derivative warrants issued	0	571,500
Outstanding	1,491,025
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding	1,171,692	600,192
Derivative warrants issued	0	0
Derivative warrants exercised	0	0
Outstanding	1,171,692	600,192

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Unrealized Gain On Warranty Derivative Liability	$462,208

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2015
Schedule of future minimum payments by operating lease [Line Items]
Remainder of 2015	$243,300
2016	283,448
2017	280,527
2018	286,754
2019	166,940
Thereafter	559,000
Total	$1,819,969

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 17, 2014	Jul. 09, 2014	Jul. 14, 2014
Schedule of commitment and contingencies [Line Items]
Operating Leases, Rent Expense, Net	$83,613	$78,466
Renewal term	10 years
Maximum [Member]
Schedule of commitment and contingencies [Line Items]
Lease Expiration Date	31-Dec-23
Minimum [Member]
Schedule of commitment and contingencies [Line Items]
Lease Expiration Date	31-Dec-19
Robert Taggart V Guy Cook Bacterin International Inc [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value			5,000,000
Middle bury Securities Llc V Bacterin International Inc [Member] | Litigation Fee [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value				80,000
Middle bury Securities Llc V Bacterin International Inc [Member] | Litigation Warrants [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value				80,000
Rodman And Renshaw Llc Debtor [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value					$150,000

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash paid during the period for:
Interest	$801,844	$930,547
Non-cash activities:
Issuance of shares related to debt issuance	$0	$1,094,999

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Director [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	$5,000
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	5,000
American Donor Services [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	$452,874	$610,514